Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Aug 29;11:2041–2053. doi: 10.2147/COPD.S114566

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Miravitlles et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Rate of moderate or severe COPD exacerbations (HCRU criteria) in less symptomatic and more symptomatic patients at Week 24, (A) less symptomatic and more symptomatic defined by E-RS score, (B) less symptomatic and more symptomatic defined by BDI score.

Note: *P≤0.05; P=0.057 vs placebo in more symptomatic patients with BDI <7; Moderate or severe exacerbations are defined as exacerbations that require treatment with antibiotics or corticosteroids and those which result in hospitalization, respectively; Exacerbations data are RR (95% CI).

Abbreviations: AB, aclidinium bromide 400 µg; BDI, Baseline Dyspnea Index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating Respiratory Symptoms; FF, formoterol fumarate 12 µg; HCRU, healthcare resource utilization; RR, rate ratio.